Neuland Labs - Company Snapshot
Neuland Laboratories Limited - Company Overview
Shuchi.P.Nahar - @shuchi_nahar
Neuland is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company operates in the market using two main business models - Generic Drug Substances (GDS) where they cater to the needs of the Generic players and Custom Manufacturing Solutions (CMS) where they primarily work with innovators by helping them bring critical products to the market. CDMO is the emerging growth segment of the company with 13 to 17 Molecules in development phase.1.
Business Performance
Neuland
lab (NLL) has posted revenue of INR 2,054mn with 13.5% YoY increase, which was
4% below. The revenue growth was mainly driven by the CMS segment, led by 32
molecules (Development + Commercialize) with speciality API segment, which grew
by 33.2% in Q1FY21. EBITDA margin expanded by 622bps to 16.5% level, which was
219bps higher than our estimate driven by 580bps improvement in gross margin
led by improved product mix.
Management
is confident to improve margin profile from current level on the back of strong
order book in CMS business, better traction in GDS business and cost
optimization measures. In terms of emerging CDMO player Company has couple of
molecules go up from 13 to about 17 in the development Phase-and from 14 to
about 15 in our commercialization phase. Some of these molecules are generating
part of the growth & some of the revenue growth is also coming from the
increase in the number of projects itself. Most of the molecules are in their
last phase of approval, that means there are more chances of approvals coming
in years. API & CMS both have healthy pipeline for future growth.
2. Revenue Growth 2019 v/s 2020
Revenue in the year 2019 was Rs. 670 Cr. Of which 54% was contributed from Prime Segment, 25% from Niche/Speciality Segment, 14% from CMS Segment and rest 7% from others Revenue in the year 2020 was Rs. 766 Cr. Of which 46% was contributed from Prime Segment, 27% from Niche/Speciality Segment, 21% from CMS Segment and rest 6% from others.
3. Key
Operating Metric – CMS Revenue Split
4.
R&D
Expenditure
In terms of
expense 2% R&D as a proportion to revenue. The R&D team has been a
crucial partner in the growth of the CMS business managing the spike in number
of projects while also making significant contribution in terms of Process
Improvement & Development (PID) work for the GDS business.
A pilot
plant has been commissioned at Unit III, which enables our team to further
accelerate the process of development of new products.
Unit III is
being operationalized which will add to the capacity and revenues from FY21.
Company commissioned a pilot plant at Unit III for use by the R&D team. It
will primarily be used to manufacture engineering/ development batches.
5.
Regulatory Filings by the Company till Date
in various Countries
880+ DMFs filed.
300+ API processes developed.
204+ patents filed.
Received USPTO patent for improved process synthesis of Paliperidone Palmitate.
6. Investment
Capital
investment during the year stood at 347.18 lacs. The Company enriched its
assets pool with new XRPDs, HPLCs, ICP MS, LCMS, and PSD equipment. This would
help increase project management and document filing capability.
It’s expected
the contribution from the high-volume segment to be gradually replaced with the
CMS segment and to register healthy revenue growth of 26.6% over FY20-22,
fuelled by the ramp-up in supplies of existing products and possible
commercialization of products in clinical trials.
7.
No of CMS Active Projects Increasing
8. Management Guidance
Capex for FY21: INR700-INR 800mn.
Unit 3: To fully commercialize from Aug 20, existing capacity sufficient to cater 2-3 years revenue. growth Awaiting more clarification from government on incentive scheme for API manufacturing.
NLL has 4 APIs out of 53 critical APIs where India has a large dependence on China.
Remain optimistic about the growth of CMS business.
9. Future Outlook
There is a lot of traction on the CMS new projects as well as good growth
in the baseline of the CMS business which is the traditional whole CMS company
had for several years.
The outlook remains positive especially because the two markets that Neuland
is focusing on Japan and North America and their pipeline of opportunity looks
quite strong the pipeline of projects that have entered the system in the last
3 to 6 months are quite advanced in nature, like say 3 molecules are about to
get into commercial.
These are opportunities which have a shorter cycle for commercialization.
So, unlike say 4-5 years ago, where the company was mostly engaged in phase I,
phase II projects now they are all in the last phase and they would go through
a natural attrition and a long cycle.
References: Neuland
Annual Report 2019-20 & 2018-19
Neuland Investor
Presentation & Conference Call Transcripts
Disclaimer: The information provided on Shuchi Nahar’s Weekend Blog is for
educational purposes only. The articles may contain external links , references
and compilation of various publicly available articles. Hence all the authors
are given due credit for the same. All copyrights and trademarks of images
belong to their respective owners and are used for Fair Educational Purpose
only.
Twitter Handle : @shuchi_nahar
This is of a great help..thanks a ton mam
ReplyDeleteAbsolutely thanks for nourishing the necessary information. I appreciate to u, all are such good information, Thanks. Pharma Manufacturing Company in Lucknow
ReplyDeleteI saw you have unique knowledge of pharmacy . Thanks for sharing such kind of information with us. Pharma Manufacturing Company in Lucknow
ReplyDeleteThanks for sharing such amazing information. I hope you keep on sharing such kind of useful information daily. Being one of thePharma Manufacturing Company in Lucknow
ReplyDelete